Clinical Hematology & Oncology: 2024

February 2–4, 2024
Hyatt Regency La Jolla at Aventine
San Diego, California

Visit www.scripps.org/HemOncCME for conference updates
Course Overview

The Scripps Clinical Hematology and Oncology conference is designed for hematologists, oncologists, surgeons, radiation oncologists, internists, and others desiring an update in these specialty areas. The primary objective of this course is to bring together clinicians and leading experts in diverse areas of hematology and oncology, affording them an intimate environment in which to discuss new clinical developments and significant advances. Our annual program is a nationally accredited continuing medical education conference and is one of the largest annual hematology/oncology meeting held in the West, among others such as ASH, ASCO and the San Antonio Breast Meeting. This conference is one of the few that combines topics in both hematology and oncology.

Educational Objectives

After attending this live activity, participants should be able to:

• Describe the clinical and molecular facets of pathogenesis, diagnostic approaches, and therapeutic modalities available for various hematologic disorders.
• Select and apply the changing approaches to hematologic malignancies, particularly as they relate to evidence-based standards of care, including innovations in diagnosis and treatment.
• Choose new therapeutic options for the treatment of several common malignancies, understanding appropriate indications and contraindications to these therapeutic approaches.
• Integrate evolving approaches to solid tumors and breast cancer from both a diagnostic, prognostic, and therapeutic perspective.
• Apply practical expertise gained from the clinical situations discussed in the panel sessions with an emphasis on data-based approaches to patients with common, but serious hematologic oncology conditions.

Target Audience

• Hematologists/Oncologists
• Medical Oncologists
• Surgeons
• Radiation Oncologists
• Internists
• And others desiring an update in these specialty areas

Accreditation and Disclosure

Physicians

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses and Nurse Practitioners

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s)™ issued by organizations accredited by the ACCME.

For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™ for attendance at structured learning activities offered by organizations accredited by the ACCME.

The American Academy of Nurse Practitioners Certified Program (AANPCP) and the American Association of Nurse Practitioners (AANP) accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Physician Assistants

PAs may claim a maximum of 20 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Pharmacists

The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA Category 1 Credit(s)™.

Commercial Support

This course is supported, in part, by educational grants from industry. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, a complete list of commercial support received will be provided to all learners who participate in the continuing education activity. For more information: www.accme.org/standards.

Course Director

Michael P. Kosty, MD, FACP, FASCO
Director, Hematology & Oncology Fellowship
Director, Thoracic Oncology
Scripps Cancer Center
La Jolla, California
### Friday, February 2, 2024

- **11 a.m.** Registration Opens
- **11:30 a.m.** Pre-Conference Symposium
  - Non-CME Activity Hosted by Agios Pharmaceuticals
- **11:30 a.m.** Pre-Conference Symposium
  - Non-CME Activity Hosted by EMD Serono

#### TOPIC: NON-MALIGNANT HEMATOLOGY
**Moderator:** Emily Nagler, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 p.m.</td>
<td>Thrombosis: 2024 Update</td>
</tr>
<tr>
<td></td>
<td>Stephan Moll, MD</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Management of Hematologic Conditions in Athletes</td>
</tr>
<tr>
<td></td>
<td>Raj Kasthuri, MD</td>
</tr>
<tr>
<td>2 p.m.</td>
<td>Management of Autoimmune, Viral and Surgical-associated Anti-PF4 Disorders</td>
</tr>
<tr>
<td></td>
<td>Ted Warkentin, MD</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Panel Discussion/Q&amp;A</td>
</tr>
<tr>
<td>3 p.m.</td>
<td>Break &amp; View Exhibits</td>
</tr>
<tr>
<td>3:15 p.m.</td>
<td>Hemolytic Anemias—Autoimmune, Membrane and Enzyme Defects</td>
</tr>
<tr>
<td></td>
<td>Ilene Weitz, MD</td>
</tr>
<tr>
<td>3:45 p.m.</td>
<td>Heavy Menstrual Bleeding: Workup for Bleeding Disorder and Management</td>
</tr>
<tr>
<td></td>
<td>Alice Ma, MD</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>Management of Simultaneous Venous and Arterial Thromboembolic Disease</td>
</tr>
<tr>
<td></td>
<td>Jori May, MD</td>
</tr>
</tbody>
</table>

- **4:45 p.m.** Panel Discussion/Q&A

#### Concurrent Breakout Sessions: Clinical Cases

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:15 p.m.</td>
<td>Breakout #1: Interesting Cases in Thrombosis</td>
</tr>
<tr>
<td></td>
<td>Stephan Moll, MD</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>Breakout #2: Interesting Cases in Platelet Disorders</td>
</tr>
<tr>
<td></td>
<td>Ted Warkentin, MD</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>Breakout #3: Interesting Cases in Bleeding</td>
</tr>
<tr>
<td></td>
<td>Alice Ma, MD</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>Breakout #4: Interesting Cases in Plasma Cell Dyscrasias</td>
</tr>
<tr>
<td></td>
<td>Morie Gertz, MD</td>
</tr>
</tbody>
</table>

- **6:15 p.m.** Adjourn

- **6:30 p.m.** Welcome & Networking Reception

### Saturday, February 3, 2024

- **6:45 a.m.** Breakfast Symposium
  - Non-CME Activity Hosted by Rigel Pharmaceuticals
- **6:45 a.m.** Breakfast Symposium
  - Non-CME Activity Hosted by Takeda Oncology
  - Introducing the First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade
  - Farshid Dayyani, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 a.m</td>
<td>Breakfast &amp; View Exhibits</td>
</tr>
<tr>
<td>7:55 a.m.</td>
<td>Welcome &amp; Announcements</td>
</tr>
<tr>
<td></td>
<td>Alan Saven, MD</td>
</tr>
</tbody>
</table>
### Conference Agenda

#### TOPIC: MALIGNANT HEMATOLOGY

**Moderator:** Alan Saven, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 a.m.</td>
<td>Myeloproliferative Neoplasms: 2024 Update</td>
<td>Brandi Reeves, MD</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Smoldering Multiple Myeloma</td>
<td>Morie Gertz, MD, MACP</td>
</tr>
<tr>
<td>9 a.m.</td>
<td>Management of MDS/AML in the Geriatric Patient</td>
<td>Courtney DiNardo, MD</td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td>Panel Discussion/Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10 a.m.</td>
<td>Break &amp; View Exhibits</td>
<td></td>
</tr>
<tr>
<td>10:30 a.m.</td>
<td>Detangling New Approaches to Hairy Cell Leukemia—A Comb or a Brush?</td>
<td>David Hermel, MD</td>
</tr>
<tr>
<td>11 a.m.</td>
<td>Advances in Frontline Treatment of FLT3-mutated AML</td>
<td>Nicholas Short, MD</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>BTK Refractory CLL</td>
<td>Susan O’Brien, MD</td>
</tr>
<tr>
<td>Noon</td>
<td>Panel Discussion/Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Lunch Symposium</td>
<td>Non-CME Activity Hosted by Pfizer</td>
</tr>
</tbody>
</table>

#### TOPIC: MALIGNANT HEMATOLOGY—NON-HODGKIN LYMPHOMAS

**Moderator:** Marin Xavier, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td>Frontline Treatment of DLBCL</td>
<td>Loretta Nastoupil, MD</td>
</tr>
<tr>
<td>2 p.m.</td>
<td>Updates in the Treatment of Relapsed DLBCL</td>
<td>Babis Andreadis, MD</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Management of Indolent NHL</td>
<td>Elizabeth Brem, MD</td>
</tr>
<tr>
<td>3 p.m.</td>
<td>Panel Discussion/Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>Break &amp; View Exhibits</td>
<td></td>
</tr>
</tbody>
</table>

#### Concurrent Breakout Sessions: Clinical Cases

<table>
<thead>
<tr>
<th>Time</th>
<th>Breakout #1: Interesting Cases in Thrombosis</th>
<th>Stephan Moll, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 p.m.</td>
<td>Breakout #2: Interesting Cases in Platelet Disorders</td>
<td>Ted Warkentin, MD</td>
</tr>
<tr>
<td></td>
<td>Breakout #3: Interesting Cases in Bleeding</td>
<td>Alice Ma, MD</td>
</tr>
<tr>
<td></td>
<td>Breakout #4: Interesting Cases in Plasma Cell Dyscrasias</td>
<td>Morie Gertz, MD</td>
</tr>
<tr>
<td>5 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td>Dinner Symposium</td>
<td>Non-CME Activity Hosted by AstraZeneca</td>
</tr>
</tbody>
</table>

#### Sunday, February 4, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 a.m.</td>
<td>Breakfast Symposium</td>
<td>Non-CME Activity Hosted by Seagen</td>
</tr>
<tr>
<td>7 a.m.</td>
<td>Breakfast &amp; View Exhibits</td>
<td></td>
</tr>
<tr>
<td>7:50 a.m.</td>
<td>Welcome &amp; Announcements</td>
<td>Sonia Ali, MD</td>
</tr>
</tbody>
</table>

#### TOPIC: BREAST CANCER, NEURO-ONCOLOGY AND MELANOMA

**Moderator:** Sonia Ali, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 a.m.</td>
<td>Breast Cancer in Pregnancy</td>
<td>Farah Nasraty, MD</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>Anthracyclines in Early Breast Cancer—Do They Still Have a Role?</td>
<td>Virginia Borges, MD</td>
</tr>
<tr>
<td>9 a.m.</td>
<td>CDK4/6 Inhibitor Therapy in Early-stage HR+/HER2- Breast Cancer</td>
<td>Sarah Sammons, MD</td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td>Panel Discussion/Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Conference Agenda

10 a.m.  Break & View Exhibits

10:30 a.m.  Neuro-Oncology: 2024 Update
Tresa McGranahan, MD, PhD

11 a.m.  Combination Immunotherapy in Melanoma
Justin Moyers, MD

11:30 a.m.  Sequencing Therapies in Metastatic Urothelial Carcinoma
Petros Grivas, MD, PhD

Noon  Panel Discussion/Q&A

12:30 p.m.  Lunch

12:30 p.m.  Lunch Symposium
Non-CME Activity Hosted by Exelixis

12:30 p.m.  Lunch Symposium
Non-CME Activity Hosted by Pfizer

TOPIC: GI AND GYN CANCERS
Moderator: Wesleigh Edwards, MD, PhD

1:30 p.m.  Artificial Intelligence in Oncology
Jacob Shreve, MD

2 p.m.  Integrating Immunotherapy into the Treatment of Cervical and Endometrial Cancers
Alexi Wright, MD

2:30 p.m.  New Approaches to Recurrent or Metastatic Ovarian Cancer
Oliver Dorigo, MD, PhD

3 p.m.  Panel Discussion/Q&A

3:30 p.m.  Break & View Exhibits

3:45 p.m.  Using ctDNA to Drive Decision Making in Adjuvant Chemotherapy of Colon Cancer
Stacey Cohen, MD

4:15 p.m.  Targeted Therapy Approaches for Upper GI Cancer
Matt Strickland, MD

4:45 p.m.  Perioperative Therapy of Resectable Non-small Cell Lung Cancer
Karen Reckamp, MD

5:15 p.m.  Panel Discussion/Q&A

5:45 p.m.  Final Adjournment

Please note: All times are listed in Pacific Time (PT). Topics, times and speakers are subject to change.

Conference Location & Hotel Information
Hyatt Regency La Jolla at Aventine
3777 La Jolla Village Drive
San Diego, CA 92122
Reservations: 888-421-1442
Phone: 858-552-1234

Discounted rooms available—see course website for details

Scan QR Code for attendance policies and full conference details:
Please make your own hotel reservations and request the Scripps conference reduced rate of $240 per night (plus tax). This low rate also includes:

- Waived resort fee
- Discounted overnight self-parking
- Complimentary guestroom internet service
- Complimentary use of the fitness center

Make your reservations early! A block of rooms is being held for us at the special rate of $240 per night until Tuesday, January 9, 2024 or until the room block fills, whichever comes first. After this date, reservations will be accepted on a space and rate availability basis only. Be sure to mention that you are attending the Scripps hematology/oncology conference when making your reservations to receive the reduced rate.

Please note: Attendees who book their room through an online, third-party service (Hotels.com®, Expedia.com®, Priceline.com®, etc.) are not eligible to receive the amenities listed above.

<table>
<thead>
<tr>
<th>Attendees</th>
<th>In-Person Rates</th>
<th>Virtual Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MD, DO, MBBS)</td>
<td>$600 thru Jan 1</td>
<td>$650 Jan 30</td>
</tr>
<tr>
<td></td>
<td>$625 Jan 2–Jan 30</td>
<td>$675 Jan 30</td>
</tr>
<tr>
<td></td>
<td>$650 Onsite after Jan 30</td>
<td>$700 Onsite after Jan 30</td>
</tr>
<tr>
<td>RN, NP, PA, Other</td>
<td>$375</td>
<td>$425</td>
</tr>
<tr>
<td>Students, Residents, Fellows</td>
<td>$150</td>
<td>$200</td>
</tr>
</tbody>
</table>

**Attendee Cancellation, Substitution and Refund**

The course tuition is refundable, minus a $100 processing fee (MD, DO, RN, PA, NP) or a $50 processing fee (Fellow, Resident, Student), if your cancellation is received in writing no later than Friday, January 19, 2024. Attendee substitutions are allowed, but notification must be made in writing by Friday, January 19, 2024. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.” No refunds shall be made for cancellations due to inclement weather.

**Registration Changes**

All registration changes (virtual to in-person or in-person to virtual) are subject to a $50 change fee when received within two weeks of the conference. If you need to make changes to your registration, please contact Scripps Conference Services & CME at 858-678-6400 or med.edu@scrippshealth.org.

**Scripps Conference Modification or Cancellation**

Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. Attendees who purchase non-refundable airline tickets do so at their own risk. Scripps encourages the purchase of travel insurance as we are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.

**Family and Guest Attendance Policy**

All conference activities and meals are exclusively reserved for paid conference attendees. Children and family members are not allowed to attend meal functions or permitted in the meeting space.

**Health and Safety Waiver and Assumption of Risk**

By completion and submission of the online registration form, participants certify they have read and fully understand the Health and Safety Waiver and Assumption of Risk Agreement.

**Recording and Photography Clause**

Scripps reserves exclusive rights to record (audio and video) and/or photograph all conference proceedings for use in marketing materials, presentations and course content sales.
Faculty

COURSE DIRECTOR

Michael P. Kosty, MD, FACP, FASCO
Director, Hematology & Oncology Fellowship
Director, Thoracic Oncology
Scripps Cancer Center
La Jolla, California

CONFERENCE FACULTY

Sonia Ali, MD
Oncologist, Hematologist
Scripps Clinic Medical Group
La Jolla, California

Babis Andreadis, MD
Professor of Medicine
University of California, San Francisco
San Francisco, California

Elizabeth Brem, MD
Assistant Professor, Division of Hematology/Oncology
University of California, Irvine
Irvine, California

Stacey Cohen, MD
Associate Professor
Fred Hutchinson Cancer Center
Seattle, Washington

Courtney DiNardo, MD, MSCE
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Oliver Dorigo, MD, PhD
Mary Lake Polan Professor
Chief, Division Gynecologic Oncology
Stanford University
Stanford, California

Wesleigh Edwards, MD, PhD
Medical Oncologist
Clinical Instructor of Medicine
Scripps Clinic Medical Group
La Jolla, California

Morie Gertz, MD, MACP
Professor, Department of Medicine
Mayo Clinic
Rochester, Minnesota

Petros Grivas, MD, PhD
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

David Hermel, MD
Medical Oncologist, Hematologist
Scripps Clinic Medical Group
La Jolla, California

Raj Kasthuri, MD, MBBS
Professor of Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Alice Ma, MD, FACP
Professor of Medicine
Fellowship Program Director
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Jori May, MD
Assistant Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Tresa McGranahan, MD, PhD
Medical Neuro Oncology
Scripps Cancer Center
La Jolla, California

Stephan Moll, MD
Professor of Medicine, Department of Medicine, Division of Hematology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Emily Nagler, MD
Hematologist
Scripps Clinic Medical Group
La Jolla, California

Farah Nasraty, MD
Hematologist, Oncologist
Scripps Clinic Medical Group
La Jolla, California

Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Susan O’Brien, MD
Professor of Medicine
University of California, Irvine
Irvine, California

Karen Reckamp, MD
Clinical Professor, Department of Medicine
Director, Division of Medical Oncology
Cedars-Sinai Medical Center
Los Angeles, California

Brandi Reeves, MD
Assistant Professor of Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Sarah Sammons, MD
Associate Director Metastatic Breast Cancer Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Alan Saven, MD
Senior Consultant, Division of Hematology & Oncology
Scripps Clinic/Scripps Green Hospital
Scripps Cancer Center
La Jolla, California

Nicholas Short, MD
Associate Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jacob Shreve, MD
Fellow, Medical Oncology & Hematology
Mayo Clinic
Rochester, Minnesota

Matthew Strickland, MD
Oncologist
Massachusetts General Hospital
Boston, Massachusetts

Ted Warkentin, MD
Professor, Pathology & Molecular Medicine
McMaster University
Hamilton, Ontario, Canada

Ilene Weitz, MD
Professor of Medicine
Jane Anne Nohl Division of Hematology
Keck-USC School of Medicine
Los Angeles, California

Alexi Wright, MD, MPH
Associate Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

Marin Feldman Xavier, MD
Clinical Professor of Medicine
Scripps Clinic Medical Group
Medical Director, Prebys Cancer Center
La Jolla, California

Faculty Disclosure

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they may be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All relevant financial relationships with ineligible companies listed for individuals in control of content have been mitigated.

A complete listing of faculty disclosures associated with this program can be found on the conference website: www.scripps.org/HemOncCME.